uniQure N.V.
uniQure N.V. (QURE) Stock Overview
Explore uniQure N.V.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
765.9M
P/E Ratio
-3.43
EPS (TTM)
$-4.38
ROE
-4.84%
QURE Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of uniQure N.V. (QURE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $4.58.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -3.43 and a market capitalization of 765.9M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Analyst Recommendations
Price Targets
Company Profile
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Matthew Craig Kapusta CPA
209
Paasheuvelweg 25a, Amsterdam
2014